colchicin – nadějný lék COVID 19

Níže uvádím stručný závěr studie – dvojitě zaslepené, randomizované a na velkém počtu pacientů, prokazující, že podání colchicinu 25mg 1-0-1 3 dny a potom 1x denně snížilo počet úmrtí na COVID 19.

Colchicin je starý dobrý lék, používá se v revmatologii, na akutní dnavý záchvat a nyní i po prodělaném infarktu. Je velmi bezpečný, ve vyšších dávkách, např. 6 tbl denně vyvolává průjmy, ale v té malé dávce 1-0-1, či jedenkrát denně, je bez výraznějších nežádoucích účinků.

Tak proč to nezkusit!!!

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19

Jean-Claude TardifNadia BouabdallaouiPhilippe L. L’AllierDaniel GaudetBinita ShahMichael H. PillingerJose Lopez-SendonProtasio da LuzLucie VerretSylvia AudetJocelyn DupuisAndré DenaultMartin PelletierPhilippe A. TessierSarah SamsonDenis FortinJean-Daniel TardifDavid BusseuilElisabeth GouletChantal LacosteAnick DuboisAvni Y. JoshiDavid D. WatersPriscilla HsueNorman E. LeporFrédéric LesageNicolas SainturetEve Roy-ClavelZohar BassevitchAndreas OrfanosJean C. GrégoireLambert BusqueChristian LavalléePierre-Olivier HétuJean-Sébastien PaquetteSylvie LevesqueMariève CossetteAnna NozzaMalorie Chabot-BlanchetMarie-Pierre DubéMarie-Claude GuertinGuy Boivinfor the COLCORONA Investigators


Background Evidence suggests the role of an inflammatory storm in COVID-19 complications. Colchicine is an orally administered, anti-inflammatory medication beneficial in gout, pericarditis and coronary disease.

Methods We performed a randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria. The patients were randomly assigned to receive colchicine (0.5 mg twice daily for 3 days and once daily thereafter) or placebo for 30 days. The primary efficacy endpoint was the composite of death or hospitalization for COVID-19.

Results A total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio, 0.79; 95.1% confidence interval (CI), 0.61 to 1.03; P=0.08). Among the 4159 patients with PCR-confirmed COVID-19, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups, respectively (odds ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04). In these patients with PCR-confirmed COVID-19, the odds ratios were 0.75 (95% CI, 0.57 to 0.99) for hospitalization due to COVID-19, 0.50 (95% CI, 0.23 to 1.07) for mechanical ventilation, and 0.56 (95% CI, 0.19 to 1.66) for death. Serious adverse events were reported in 4.9% and 6.3% in the colchicine and placebo groups (P=0.05); pneumonia occurred in 2.9% and 4.1% of patients (P=0.02). Diarrhea was reported in 13.7% and 7.3% in the colchicine and placebo groups (P<0.0001).

Conclusion Among non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization. (COLCORONA number: NCT04322682)

Competing Interest Statement

JCT reports grants from Government of Quebec, National Heart, Lung, and Blood Institute of the U.S. National Institutes of Health (NIH), the Montreal Heart Institute Foundation, from Bill and Melinda Gates Foundation, Amarin, Esperion, Ionis, Servier, RegenXBio; personal fees from Astra Zeneca, Sanofi, Servier; and personal fees and minor equity interest from Dalcor. In addition, JCT’s institution has submitted a patent Methods of treating a coronavirus infection using Colchicine pending and a patent Early administration of low-dose colchicine after myocardial infarction pending. JCT has waived his rights in all patents related to colchicine and does not stand to benefit financially if colchicine becomes used as a treatment for COVID-19. MPD and JCT have a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcor, no royalties received, a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcor, no royalties received, and a patent Methods for using low dose colchicine after myocardial infarction with royalties paid to Invention assigned to the Montreal Heart Institute. NB reports personal fees from AstraZeneca; BS reports grants from NIH NHLBI; MHP reports grants from Hikma Pharmaceuticals, Horizon Therapeutics, and personal fees from Horizon Therapeutics; JLS reports grants from Bayer, Pfizer, Amgen, Boheringer Ingelheim and personal fees from Menarini; AYD reports personal fees from CAE Healthcare and Masimo, grants from Edwards; PH reports grants from NIH, Montreal Heart Institute, Gilead, and other from Merck; AO reports grants from the COVID-19 Therapeutics Accelerator; JSP reports personal fees from Universite Laval; MPD reports personal fees and other from Dalcor and personal fees from GlaxoSmithKline, other from AstraZeneca, Pfizer, Servier, Sanofi. Other authors have nothing to declare.

Clinical Trial


Funding Statement

The study was funded by the Government of Quebec, the Bill and Melinda Gates Foundation, the National Institutes of Health and philanthropist Sophie Desmarais. The study medication and matching placebo were provided by Pharmascience (Montreal), which had no role in the design or conduct of the trial or the preparation or review of the manuscript. The first author (JCT) and lead statistician (MCG) prepared the first draft of the manuscript, had full access to the trial database, generated statistical analyses, made the decision to submit the manuscript for publication, and assume responsibility for the accuracy and completeness of the data and analyses and for the fidelity to the protocol.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.


The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The protocol was approved by the Montreal Heart Institute research ethics committee and all institutional review boards at all centers involved in the 6 countries that participated in the trial.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.


I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).


I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.


Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv